Sign in to view content

Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema

John W. Kitchens, MD

Video
Published 2022

Related

Efficacy, Safety, and Durability of Faricimab in Macular Edema Due to Retinal Vein Occlusion: 72-Week Results From the Phase 3 BALATON and COMINO Trials
Carl J Danzig, MD
Annual Meeting Talks
2024
Real World Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Carl J Danzig, MD
Annual Meeting Talks
2022
Preclinical Analysis of a Novel Trispecific Antibody, RO-104, for Use in Retinal Neovascular Disease
Subhransu K. Ray, MD, PhD
Annual Meeting Talks
2024

Category: Diabetic Retinopathy

See more